Reduce the Risk of Recurrence in Early Stage HER2+ Breast Cancer

FDA Approves Ribociclib (Kisqali) for Stage 2-3 HR+/HER2- Breast Cancer at Higher Risk of RecurrenceПодробнее

Reducing the Risk of Recurrence In HR+/HER2- Early Breast Cancer Requires Action: MDT Clinical Ca...Подробнее

Dr Thompson on the Necessity of Surgery and Radiation Therapy in Early-Stage Breast CancerПодробнее

10. Early HER2-Positive Breast CancerПодробнее

24 June 2023 FB Live Health Talk-Risk of Recurrence in HER2+ Breast CancerПодробнее

Early Stage Breast Cancer - A Clinical Overview and Research Briefing with Virginia Borges, MD, MMScПодробнее

NEW BREAST CANCER TREATMENT FOR PEOPLE WITH HR+/HER2-EARLY BREAST CANCER WITH DR. NIKITA C. SHAH, MDПодробнее

Assessing Risk in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: How to Approach Ch...Подробнее

FDA Approves Kisqali / Ribociclib for Early High-Risk Breast Cancer ESMO 2024Подробнее

HER2-Negative Breast Cancer | Beyond the Guidelines: Clinical Investigator Perspectives on the Ma...Подробнее

Conceptualizing Guidelines to Manage Patients with HR–Positive, HER2-Negative Early Breast CancerПодробнее

ClarifyingComplexities of ExpandingTreatmentOptionsFor AdvancedAndEarly-Stage HR+/HER2- BreastCancerПодробнее

Systemic therapy in operable HER2 positive breast cancerПодробнее

N9831 trial: genes associated with early and late recurrence in HER2+ breast cancerПодробнее

Drug shows promise in preventing cancer recurrence | ABCNLПодробнее

Who gets Breast Cancer Recurrences? - with Dr TashaПодробнее

Adjuvant Therapy | 2023 Best of Breast ConferenceПодробнее

HER2DX risk-score in early-stage HER2-positive breast cancerПодробнее

Lightning Updates | 2023 Best of Breast ConferenceПодробнее

Breast Cancer Recurrence Video 1080WebShareNameПодробнее